IFN-γ is licensed to treat chronic granulomatous disease (Todd and Goa, 1992) and is discussed as a treatment for idiopathic pulmonary fibrosis (Smaldone, 2018). This evidence concerns the gene IFNG and pulmonary fibrosis.